|
CZ201532A3
|
|
Process for preparing extremely pure rilpivirine and salt thereof
|
|
CZ2014792A3
|
|
Process for preparing, isolation and purification of pharmaceutically usable AHU-377 forms
|
|
CZ2014773A3
|
|
Salts of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
|
|
CZ2014708A3
|
|
Bedaqujiline salts
|
|
CZ2014702A3
|
|
Process for preparing extremely pure azilsartan
|
|
CZ2014680A3
|
|
Process for preparing glycopyrronium bromide
|
|
CZ2014634A3
|
|
Canagliflozin and cyclodextrin complexes
|
|
CZ2014502A3
|
|
Sofosbuvir novel form and process for preparing thereof
|
|
CZ305436B6
|
|
Solid form of ivabradine hydrochloride and (R)-mandelic acid and pharmaceutical composition thereof
|
|
CZ2014475A3
|
|
Process for preparing abiraterone acetate of high purity applicable in industrial range
|
|
CZ2014471A3
|
|
Process for preparing vortioxetine
|
|
CZ2014400A3
|
|
Fesoterodine stabilized formulation
|
|
CZ2014271A3
|
|
Novel salts of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitrile
|
|
CZ2014232A3
|
|
Process for preparing enzalutamide
|
|
CZ2014188A3
|
|
Novel forms of aclidinium chloride and process for preparing thereof
|
|
CZ2014177A3
|
|
Process for preparing saxagliptin
|
|
CZ201497A3
|
|
Enzalutamide crystalline form
|
|
CZ2013985A3
|
|
Stable pharmaceutical composition containing tenofovir disoproxil fumarate
|
|
CZ2013943A3
|
|
Vemurafenib crystalline forms
|
|
CZ2013866A3
|
|
Novel crystalline form of ticagrelor synthesis intermediate and process for preparing thereof
|
